Phase I clinical trial of TQB3915 tablets for advanced malignant solid tumors
The company Chia Tai Tianqing Pharmaceutical Group Co., Ltd is enrolling patients into the clinical trial investigating Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors.
TQB3915 is a selective estrogen receptor covalent antagonist, by covalently binding to estrogen receptor, by changing the conformation of ERα, blocking intracellular signal transmission, thereby inhibiting the growth of tumor cells.
TQB3915 binds to estrogen receptors through covalent bonds, and blocks intracellular signal transmission by changing the conformation of ERα, thereby inhibiting the growth of tumor cells.
The trial is designed to enroll male and female 18 Years to 75 Years and is being conducted in the Sun Yat-Sen University Cancer Canter, Guangzhou, Guangdong, China; Henan Cancer Hospital, Zhengzhou, Henan, China; First Affiliated Hospital with Nanjin Medical University (Jiangsu Province Hospital), Nanjing, Jiangsu, China.
The study start date is June 2022.
This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05416359 or https://clinicaltrials.gov/ct2/show/NCT05416359.
